Melanocyte Stimulating Hormone Receptor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)- Pipeline Review, H2 2019’, provides in depth analysis on Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders and Oncology under development targeting Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

– The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects

– The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Aequus BioPharma Inc

Clinuvel Pharmaceuticals Ltd

Eton Pharmaceuticals Inc

Palatin Technologies Inc

SolaranRx Inc

SynAct Pharma AB”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Overview

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Companies Involved in Therapeutics Development

Clinuvel Pharmaceuticals Ltd

MallInckrodt Plc

Palatin Technologies Inc

SolaranRx Inc

SynAct Pharma AB

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drug Profiles

afamelanotide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1189 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUV-9900 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8177 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8331 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-1177 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLRX-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Dormant Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Discontinued Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Product Development Milestones

Featured News & Press Releases

Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Jun 25, 2018: Clinuvel Completes Scenesse FDA Filing

Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies

Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)

Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel

May 23, 2018: Nice Maintains Its Position Not To Recommend Scenesse For Reimbursement

May 14, 2018: CLINUVEL Provides Regulatory Update

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on its Drug Candidate PL-8177at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel

Apr 03, 2018: Palatin Technologies presents preclinical oral formulation data on PL-8177, an investigational melanocortin receptor 1 Agonist for inflammatory bowel disease

Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert

Mar 19, 2018: Clinuvel Holds European Erythropoietic Protoporphyria (EPP) Expert Meeting

Feb 05, 2018: Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist

Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Aequus BioPharma Inc, H2 2019

Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2019

Pipeline by Eton Pharmaceuticals Inc, H2 2019

Pipeline by Palatin Technologies Inc, H2 2019

Pipeline by SolaranRx Inc, H2 2019

Pipeline by SynAct Pharma AB, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports